Epidemiology and Survival of Patients With Optic Pathway Gliomas: A Population-Based Analysis

Huanbing Liu†, Yong Chen†, Xiaowei Qin†, Zheng Jin, Yining Jiang and Yubo Wang*

Department of Neurosurgery, First Affiliated Hospital of Jilin University, Changchun, China

Background: We aimed to analyze the epidemiology and outcomes of pediatric patients and adult patients with optic pathway gliomas in the United States using a population-based method.

Methods: Data for patients with optic pathway gliomas diagnosed between 2000 and 2018 were extracted from the SEER database. We divided the patients into a pediatric group and an adult group. Descriptive analyses were conducted to analyze demographic and clinical characteristics and treatment. We used the chi-square test to evaluate differences between pediatric and adult patients with optic pathway gliomas. The possible prognostic indicators were analyzed by Kaplan–Meier curves and Cox proportional hazards models.

Results: Optic pathway gliomas represented 86.6% of all lesions originating from the optic pathway. In total, 1257 cases of optic pathway gliomas were included in our study. Pediatric patients accounted for 83.7% in this cohort, and most of the patients were diagnosed at 1-4 years old. Chemotherapy was chosen most often for pediatric patients, but radiation therapy was chosen most often for adult patients. Pilocytic astrocytoma accounted for 59.1% of pediatric patients and 37.5% of adult patients. The overall survival (OS) rates were 94.8% 5 years after diagnosis and 93.0% 10 years after diagnosis.

Survival analysis showed that surgery, radiation and chemotherapy did not help patients obtain a better prognosis. Overall, pediatric patients had a better prognosis.

Conclusion: Optic pathway gliomas are relatively rare lesions with good prognosis. They mostly affect children, and pilocytic astrocytoma is the most common histological diagnosis. Highly individualized treatment is essential for such patients.

Keywords: epidemiology, survival, SEER program, CNS disease, optic pathway glioma
INTRODUCTION

Gliomas account for almost 30% of all primary brain tumors and are responsible for the majority of deaths from primary brain tumors (1). Optic pathway gliomas (OPGs), also known as optic nerve gliomas, are relatively rare lesions that comprise 1% of all intracranial tumors and 3–5% of all pediatric brain tumors (2, 3). OPGs are believed to be the most common tumor of the optic nerve, and they are confined to the structures of the visual pathway (2, 4, 5). The Surveillance, Epidemiology, and End Results (SEER) Program is a clinical database funded by the National Cancer Institute (NCI) that was created to collect cancer incidence, prevalence, and survival data in the United States, covering approximately 35% of the United States population (6). We conducted this population-based study to analyze the epidemiology and outcome of patients with OPGs using data from the SEER program.

METHOD

Detailed Clinical Data Extraction

The SEER database is available to the public for research purposes, and no ethics committee approval or informed consent was required to perform this analysis. Patients diagnosed with glioma originating from the optic pathway (C73.0-optic nerve) from 2000 to 2018 were included. The term glioma was defined by setting the variable “Histology recode - broad groupings” as “9380-9489: gliomas”. SEER*Stat (Surveillance Research Program, National Cancer Institute SEER*Stat software version 8.3.9) was used to extract detailed patient data from SEER Research Plus Data, 18 Registries (November 2020 submission) (7).

Variables and Population Analysis

Demographic and clinical variables included age at diagnosis (0-19 years and older than 19 years), sex (male, female), race (white, other), laterality (left, right, bilateral and unknown), behavior code (benign and borderline, malignant), surgery (yes, none/unknown), radiation therapy (yes, none/unknown), chemotherapy (yes, none/unknown), survival months and vital status (alive, dead). First, we analyzed the distribution of patients by age at diagnosis. Second, we divided the patients into pediatric and adult groups and evaluated the differences in demographic and clinical characteristics and treatment between pediatric and adult patients with OPGs by the chi-square test, and statistical significance was set to p<0.05. Third, we analyzed the differences in treatment patterns between the two groups. Fourth, we analyzed the distribution of patients by pathology type, and pathology type was recorded according to the code “Histology recode - Brain groupings”. Only patients with available histology were included to make the results more accurate.

Survival Analysis

Survival to 5 and 10 years after diagnosis was calculated using the Kaplan–Meier method. The log-rank test and univariate Cox proportional hazard models were performed to estimate possible independent prognostic factors associated with overall survival (OS) in patients with OPGs, and statistical significance was set to p<0.05. OS was defined as the time from diagnosis to death from any cause. All the data were analyzed using SPSS Statistics, Version 25 (IBM SPSS Statistics for Windows, Version 25 Armonk, NY: IBM Corp). Survival analysis was first conducted for the entire cohort. To make the sample more homogeneous, survival analysis was performed for pediatric patients and adult patients separately.

RESULTS

Population Analysis

In total, 1451 cases of primary lesions originating from the optic nerve were indexed between 2000 and 2018, and 1257 cases were identified as gliomas, which represented 86.6% of all patients with lesions originating from the optic nerve. Pediatric patients (≤19 years old) accounted for 83.7% of the cohort, and most of the patients were diagnosed at 1-4 years old (Figure 1). There

**FIGURE 1** | Distribution of the patients by age at diagnosis.
were 662 female patients (52.7%) and 595 male patients (47.3%), and white patients accounted for approximately 82.8% (n=1041) of all patients. Overall, 43.4% of the tumors (n=89) originated from the left side in adult patients, and 41.6% of the tumors (n=438) were bilateral or unknown in pediatric patients. There was a statistically significant difference between the pediatric and adult populations in laterality and treatment options (Table 1). A total of 63.1% of the patients (n=793) chose observation for treatment. Except for observation, pediatric patients mostly chose chemotherapy, and adult patients mostly chose radiation therapy (Table 2). We analyzed the pathology type of the patients with available histology, and 283 cases were included (80 adults and 203 pediatric patients). Pilocytic astrocytoma accounted for 53.0% of the patients with available histology (59.1% for pediatric patients and 37.5% for adult patients). Overall, 17.5% of the adult patients were diagnosed with glioblastoma, and no pediatric patients were diagnosed with glioblastoma (Table 3).

**Survival Analysis**

The OS rates were 94.8% 5 years after diagnosis and 93.0% 10 years after diagnosis. The OS of the whole cohort is shown in Figure 2A, as determined by a Kaplan–Meier curve. The results of the log-rank test indicated that pediatric patients had better OS than adult patients (Figure 2B). The results for the log-rank tests and univariate Cox proportional hazard models, including the hazard ratios (HRs) and 95% confidence intervals (CIs), are presented in Table 5.

**DISCUSSION**

OPGs are relatively rare and mostly affect children (8). Several systematic reviews have been reported (5, 9), but population-based studies of OPGs have seldom been described. The SEER database provides a sufficient amount of publicly available information for research purposes, enabling us to conduct this population-based analysis to better understand OPGs. To ensure that sufficient information was included, we chose the latest database and set the period as 2000-2018.

In our study, we found that more than 80% of the patients were diagnosed before 20 years of age. However, the oldest patient was 101 years old, and OPGs can be diagnosed at any age. Survival analysis showed that age at diagnosis was an independent prognostic factor, and pediatric patients had a better prognosis than adult patients. The predominance of white patients was also noted, as in other reports (10). It has been reported that 85% of OPGs are located in the optic nerves and/or chiasm, and 15% are located in the optic tracts and radiation (11). In addition, chiasmatic/hypothalamic tumor sites have been reported as risk factors for long-term visual deterioration (12). We could not obtain information on whether the OPGs originated from the optic nerve, chiasm or optic tracts. Therefore, we analyzed laterality instead, and we found that 41.6% of the tumors in the pediatric group did not originate from the left or right. We deduced that these tumors originated from the chiasm. In addition, the influence of laterality was not significant in the survival analysis; further

---

**TABLE 1** Demographic and clinical characteristics of patients with optic pathway gliomas.

| Variables          | Adult    | Pediatric | Total  | P value |
|--------------------|----------|-----------|--------|---------|
| **Sex**            |          |           |        |         |
| Female             | 119(58.0%) | 543(51.6%) | 662(52.7%) | 0.091   |
| Male               | 86(42.0%) | 509(48.4%) | 595(47.3%) |         |
| **Race**           |          |           |        |         |
| White              | 165(80.5%) | 876(83.3%) | 1041(82.8%) | 0.334   |
| Others             | 40(19.5%) | 176(16.7%) | 216(17.2%) |         |
| **Laterality**     |          |           |        | <0.001  |
| Right              | 89(43.4%) | 313(29.8%) | 402(32.0%) |         |
| Left               | 63(30.7%) | 301(28.6%) | 364(29.0%) |         |
| Bilateral and unknown | 53(25.9%) | 439(41.6%) | 491(39.1%) |         |
| **Behavior code**  |          |           |        | 0.461   |
| Benign and borderline | 146(8.8%) | 88(8.4%)   | 234(8.1%)  |         |
| Malignant          | 191(93.2%) | 964(91.6%) | 1155(91.9%) |         |
| **Surgery**        |          |           |        | <0.001  |
| Yes                | 40(19.5%) | 111(10.6%) | 151(12.0%) |         |
| None/Unknown       | 165(80.5%) | 941(89.4%) | 1106(88.0%) |         |
| **Radiation**      |          |           |        | <0.001  |
| Yes                | 76(37.1%) | 19(1.8%)   | 95(7.6%)   |         |
| None/Unknown       | 129(62.9%) | 1033(88.2%) | 1162(92.4%) |         |
| **Chemotherapy**   |          |           |        | <0.001  |
| Yes                | 30(14.6%) | 298(28.3%) | 328(26.1%)  |         |
| None/Unknown       | 175(85.4%) | 754(71.7%) | 929(73.9%)  |         |
high-quality studies are needed to address the potential role of laterality at the time of OPG presentation on OS.

Although most of these tumors were pilocytic astrocytomas, we also found that some of the OPGs were glioblastomas, accounting for 17.5% of the adult patients with available histology. Because only 22.5% of the diagnoses were confirmed by available histology, we did not include pathology type in the survival analysis. In 2020, Kinori et al. (13) reported that children with neurofibromatosis type 1 (NF-1)-associated OPGs who had a normal initial exam had excellent long-term visual function. Pediatric patients with sporadic OPGs, however, have been reported to have significant long-term visual impairment (14).

A systematic review from Opocher et al. (5) showed that solid evidence is needed to prove whether NF-1 is an independent prognostic factor. Unfortunately, information on NF-1 was not included in the SEER program; thus, we could not conduct such an analysis. However, our survival analysis results showed that pediatric patients have better OS than their adult counterparts.

The treatment for OPGs remains controversial (9, 15, 16). According to a previous report, observation is suggested for

---

**TABLE 2** | Analysis of treatment patterns chosen by patients with optic pathway gliomas.

| Treatment                             | Adult     | Pediatric | Total     |
|---------------------------------------|-----------|-----------|-----------|
| Chemotherapy                          | 8(3.9)    | 237(22.5) | 245(19.5) |
| Chemotherapy and Radiation            | 13(6.3)   | 40(4.4)   | 17(1.4)   |
| Observation                           | 101(49.3) | 692(65.8) | 793(63.1) |
| Radiation                             | 43(21.0)  | 80(8.8)   | 51(4.1)   |
| Surgery                               | 19(9.3)   | 51(4.8)   | 70(5.6)   |
| Surgery and Chemotherapy              | 10(5.0)   | 53(0.5)   | 54(4.3)   |
| Surgery and Radiation                 | 12(5.9)   | 30(3.0)   | 15(1.2)   |
| Surgery + Radiation + Chemotherapy    | 8(3.9)    | 40(4.4)   | 12(1.0)   |
| Total                                 | 205(100.0)| 1052(100.0)| 1257(100.0)|

**TABLE 3** | The distribution of the patients with histology records.

| Histology code                           | Adult     | Pediatric | Total     |
|------------------------------------------|-----------|-----------|-----------|
| Anaplastic astrocytoma                   | 7(8.8)    | 1(0.5)    | 8(2.8)    |
| Astrocytoma, NOS                         | 10(12.5)  | 13(6.4)   | 23(8.1)   |
| Benign and malignant neuronal/glial, neuronal and mixed | 0         | 1(0.5)    | 1(0.4)    |
| Diffuse astrocytoma (protoplasm, fibrillary) | 0         | 1(0.5)    | 1(0.4)    |
| Embryonal/primitive/meduloblastoma       | 0         | 1(0.5)    | 1(0.4)    |
| Ependymoma/anaplastic ependymoma         | 1(1.3)    | 1(0.5)    | 1(0.4)    |
| Glioblastoma                             | 14(17.5)  | 0         | 14(4.9)   |
| Glioma, NOS                              | 18(22.5)  | 64(31.5)  | 82(29.0)  |
| Mixed glioma                             | 0         | 2(1.0)    | 2(0.7)    |
| Pilocytic astrocytoma                    | 30(37.5)  | 120(59.1) | 150(53.0) |
| Total                                    | 80(100.0) | 203(100.0) | 283(100.0) |

---

**FIGURE 2** | Kaplan–Meier survival analysis: (A) The overall survival for the whole cohort. The survival analysis of patients classified based on age at diagnosis (B).
patients with neurofibromatosis type 1 (NF-1) or nonprogressive gliomas. When pronounced proptosis and blindness are present or a mass effect or hydrocephalus is observed, surgery is usually considered appropriate (15, 16). Our results show that most (63.1%) of the treatment regimens were no/unknown because the codes for radiation and chemotherapy in the SEER database did not distinguish between “no” and “unknown” treatment. However, the surgery codes showed that only 14 of the 1257
cases (1.1%) were unknown. Therefore, we speculate that observation is recommended for most patients. The survival analysis revealed that the patients who underwent surgery had a worse prognosis. We speculate that the patients had larger tumors or more serious visual damage; thus, although surgery was conducted, the prognosis was not better than that of their counterparts. Because radiation-related complications, including endocrinopathy, vasculopathy, and cognitive decline, occur in young children, radiation therapy has been gradually abandoned for pediatric patients with OPGs, and chemotherapy has been increasingly adopted (17). Our result of the treatment analysis was coincident with previous reports, but the patients who received chemotherapy also had a worse prognosis. Moreno et al. (9) conducted a systematic review in 2010 and found that treatment with chemotherapy does not improve the resulting vision in the majority of children with OPGs. However, indication bias may exist in our study. Perhaps the worse survival of patients with treatment is due to the severity of the tumor itself and not the treatment. We agree that the treatment of OPGs requires a multidisciplinary approach in which all treatment options are implemented in a highly individualized manner (18).

Except for possible bias and inaccurate data, we have to consider other limitations of our analysis. First, information about tumor progression and ophthalmologic examinations, such as visual acuity and visual field, was limited and is very important for patients with OPGs. Second, the SEER program provided limited information about the genetics of central nervous system tumors, and NF-1 is believed to be associated with the survival of patients with OPGs (19). Third, detailed information about surgery, radiation and chemotherapy was limited, and our results of the survival analysis therefore could not explain the specific condition of individual patients. Despite these limitations, this population-based study can provide helpful information and a better understanding of the epidemiology and survival of patients with OPGs.

CONCLUSION
OPGs are relatively rare lesions, representing 86.6% of all patients with lesions originating from the optic pathway. They mostly affect children, and pilocytic astrocytoma is the most common histological diagnosis. In our cohort, the prognosis was good, and the OS rate at 10 years after diagnosis was 93.0%. Observation is recommended for most patients. Based on the SEER data, surgery, radiation and chemotherapy showed no evidence of improving OS. Highly individualized treatment is essential for patients with OPGs.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS
YW: Conceptualization, methodology, and writing—reviewing and editing. ZJ, YJ, and YW: Data curation, software, and validation. HL, YC, XQ, and YW: Writing—original draft preparation. Writing—reviewing and editing. All authors contributed to the article and approved the submitted version.

REFERENCES
1. Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. Nat Rev Dis Primers (2015) 1:15017. doi: 10.1038/nrdp.2015.17
2. Rasool N, Odel JG, Kazim M. Optic Pathway Glioma of Childhood. Curr Opin Ophthalmol (2017) 28:289–95. doi: 10.1097/ICO.0000000000000370
3. Jahraus CD, Tarbell NJ. Optic Pathway Gliomas. Pediatr Blood Cancer (2006) 46:586–96. doi: 10.1002/pbc.20655
4. Avery RA, Mansoor A, Idrees R, Trimboli-Heidler C, Ishikawa H, Packer RJ, et al. Optic Pathway Glioma Volume Predicts Retinal Axon Degeneration in Neurofibromatosis Type 1. Neurology (2016) 87:2403–7. doi: 10.1212/WNL.0000000000003402
5. Oprocher E, Kremer LC, Da Dalt L, van de Wetering MD, Viscardi E, Caron HN, et al. Prognostic Factors for Progression of Childhood Optic Pathway Glioma: A Systematic Review. Eur J Cancer (Oxford England: 1990) (2006) 42:1807–16. doi: 10.1016/j.ejca.2006.02.022
6. Overview of the SEER Program (2020). Available at: https://seer.cancer.gov/about/overview.html (Accessed Jan, 2020).
7. Surveillance, Epidemiology, and End Results (SEER) Program, (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 18 Registries, Nov 2020 Sub (2000-2018) - Linked To County Attributes - Total U.S., 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission.
8. Huang M, Patel I, Patel BC. Optic Nerve Glioma. StatPearls. StatPearls Publishing Copyright © 2020. Treasure Island (FL: StatPearls Publishing LLC. (2020).
9. Moreno L, Bautista F, Ashley S, Duncan C, Zacharoulis S. Does Chemotherapy Affect the Visual Outcome in Children With Optic Pathway Glioma? A Systematic Review of the Evidence. Eur J Cancer (Oxford England: 1990) (2010) 46:2253–9. doi: 10.1016/j.ejca.2010.03.028
10. Peckham-Gregory EC, Montenegro RE, Stevenson DA, Viskochil DH, Scheurer ME, Lupo PJ, et al. Evaluation of Racial Disparities in Pediatric Optic Pathway Glioma Incidence: Results From the Surveillance, Epidemiology, and End Results Program, 2000–2014. Cancer Epidemiol (2018) 54:90–4. doi: 10.1016/j.canep.2018.04.005
11. Khatta S, Gutmann DH, Packer RJ. Neurofibromatosis Type 1 and Optic Pathway Glioma: Molecular Interplay and Therapeutic Insights. Pediatr Blood Cancer (2018) 65:3. doi: 10.1002/pbc.26838
12. Dodgshun AJ, Elder JE, Hansford JR, Sullivan MJ. Long-Term Visual Outcome After Chemotherapy for Optic Pathway Glioma in Children: Site and Age Are Strongly Predictive. Cancer (2015) 121:4190–6. doi: 10.1002/cncr.29649

Frontiers in Oncology | www.frontiersin.org February 2022 | Volume 12 | Article 789856
13. Kinori M, Armarnik S, Listernick R, Charrow J, Zeid JL. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More. *Am J Ophthalmol* (2021) 221:91–6. doi: 10.1016/j.ajo.2020.03.053

14. Wan MJ, Ullrich NJ, Manley PE, Kieran MW, Goumnerova LC, Heidary G. Long-Term Visual Outcomes of Optic Pathway Gliomas in Pediatric Patients Without Neurofibromatosis Type 1. *J Neuro-Oncol* (2016) 129:173–8. doi: 10.1007/s11060-016-2163-4

15. Astrup J. Natural History and Clinical Management of Optic Pathway Glioma. *Br J Neurosurg* (2003) 17:327–35. doi: 10.1080/02688690310001601216

16. Cardellicchio S, Bacci G, Farina S, Genitori L, Massimino M, de Martino M, et al. Low-Dose Cisplatin-Etoposide Regimen for Patients With Optic Pathway Glioma: A Report of Four Cases and Literature Review. *Neuropediatrics* (2014) 45:42–9. doi: 10.1055/s-0033-1360482

17. Awdeh RM, Kiehna EN, Drewry RD, Kerr NC, Hak BG, Wu S, et al. Visual Outcomes in Pediatric Optic Pathway Glioma After Conformal Radiation Therapy. *Int J Radiat Oncol Biol Phys* (2012) 84:46–51. doi: 10.1016/j.ijrobp.2011.10.067

18. Nair AG, Pathak RS, Iyer VR, Gandhi RA. Optic Nerve Glioma: An Update. *Int Ophthalmol* (2014) 34:999–1005. doi: 10.1007/s10792-014-9942-8

19. Bhatti MT, Mansukhani SA, Chen JJ. Microcystic Macular Edema in Optic Nerve Glioma. *Ophthalmology* (2020) 127(7):930. doi: 10.1016/j.ophtha.2020.03.017

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Liu, Chen, Qin, Jin, Jiang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*